Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese CRO ShangPharma Moves Into Biologics To Follow Customer Trend

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of Chinese contract research organization ShangPharma this week outlined plans to continue expanding the outfit's drug and biopharmaceutical research services through next year to attract more of the top international players

You may also be interested in...



China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors

China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas

China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors

China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas

Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool

BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership

Related Content

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel